QRISK2

QRISK2 calculates an individual's 10-year risk of cardiovascular disease (CVD), specifically the likelihood of heart attack or stroke, using demographic, clinical, and lifestyle variables.

Key Features:

• Risk estimation: Calculates a 10-year CVD risk score based on a defined set of 16 variables including demographic information, medical history, and lifestyle factors.
• Variable scope: Incorporates demographic, medical history and lifestyle inputs to provide personalized risk assessment.
• Target population: Intended for individuals without pre-existing coronary heart disease (including angina or prior myocardial infarction) and without prior stroke or transient ischemic attack.
• NAFLD cohort data: Has been applied in a retrospective study of 1,535 biopsy-proven nonalcoholic fatty liver disease (NAFLD) patients collected across ten Asian centers in eight countries (PMID: 32476802).
• Predictive associations: In the cited study, advanced fibrosis stages (F3 and F4) were identified as significant predictors of increased 10-year CVD risk, while gamma-glutamyl transferase (GGT) alone did not predict higher QRISK2 scores.

Scientific Applications:

• General population risk stratification: Estimating 10-year risk of heart attack or stroke in individuals without established coronary heart disease or prior cerebrovascular events.
• NAFLD risk assessment: Assessing cardiovascular risk among patients with biopsy-proven NAFLD and examining associations with liver fibrosis stage (PMID: 32476802).
• Biomarker association studies: Comparing predicted QRISK2 scores with biochemical markers such as gamma-glutamyl transferase (GGT) to evaluate biomarker–risk relationships in clinical cohorts.

Methodology:

Calculates 10-year CVD risk from a specified set of 16 variables and has been used in retrospective association analyses comparing QRISK2 scores with gamma-glutamyl transferase (GGT) levels and fibrosis stage in a cohort of 1,535 biopsy-proven NAFLD patients (PMID: 32476802).